IE 11 is not supported. For an optimal experience visit our site on another browser.

Sunesis to Present at the 10th Annual Needham Healthcare Conference

SOUTH SAN FRANCISCO, Calif., March 30, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the 10th Annual Needham Healthcare Conference on Tuesday, April 5th at 4:00 PM Eastern Time at The New York Palace Hotel in New York City.
/ Source: GlobeNewswire

SOUTH SAN FRANCISCO, Calif., March 30, 2011 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the 10th Annual Needham Healthcare Conference on Tuesday, April 5th at 4:00 PM Eastern Time at The New York Palace Hotel in New York City.

A live webcast of the presentation will be available on the Sunesis website at . A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, vosaroxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit .

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

The Sunesis Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8773

CONTACT: Investor and Media Inquiries: Andrea Rabney Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717